Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Biologics v/s Biosimilars), By Product Type (Branded v/s Generics), By Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn’s Disease, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Others), By End Users (Hospitals& Clinics, Home Healthcare, Others), By Region, Forecast & Opportunities, 2028

December 2022 | 116 pages | ID: AA8EB94CA406EN
TechSci Research

Abstracts

Global adalimumab market is expected to undergo significant growth during the forecast period, 2024-2028. The rising prevalence of arthritis coupled with large number of clinical trials is impelling the growth of the market. Adalimumab is an anti-TNF drug which is used for the treatment of rheumatoid arthritis, psoriatic arthritis, psoriasis and ulcerative colitis. Adalimumab lowers the chances of inflammatory response by binding to a TNF?. Adalimumab are currently being marketed in over 60 countries around the world.

Several companies are undergoing extensive clinical trials and R&D activities, which in turn, is expected to augment a major growth factor for global adalimumab market. The reimbursement coverage and well-defined regulatory guidelines are further expected to fuel the market growth through 2028. However, patent expiration of blockbuster drugs is expected to slow down the market growth. Besides, side effects associated with the drugs is expected to restrain the growth of the market.

Global adalimumab market is segmented based on based on type, product type, therapeutic area, distribution channel, end user, company and region. Based on therapeutic area, the market is categorized into rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn’s disease, and others. Among them, the rheumatoid arthritis is expected to dominate the global market owing to high prevalence among elderly population.

Regionally, North America is expected to dominate the global adalimumab market followed by Europe. The advanced healthcare infrastructure and well-organized regulatory framework in these two regions is making them a lucrative market for adalimumab manufacturers.

Major companies operating in global adalimumab market include Abbvie Inc., Pfizer Inc., Amgen Inc., Novartis AG, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd, Boehringer Ingelheim International GmbH, Mylan N.V., Hetero Biopharma Ltd., and Samsung Bioepis Co Ltd. The market players are undergoing extensive clinical trials to test the safety and efficacy of the adalimumab in treatment of various diseases.

Objective of the Study:

• To analyse and forecast the market size of global adalimumab market.
• To forecast global adalimumab market based on based on type, product type, therapeutic area, distribution channel, end user, company and region.
• To identify drivers and challenges for global adalimumab market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global adalimumab market.
• To identify and analyse the profile of leading players operating in the global adalimumab market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of adalimumab manufacturing companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated global adalimumab market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

• Adalimumab manufacturers, companies, partners, hospitals pharmacy/retail pharmacy and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, industry associations, forums and alliances related to adalimumab
• Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as adalimumab manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global adalimumab market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Global Adalimumab Market, By Type:
• Biologics
• Biosimilar
• Global Adalimumab Market, By Product Type:
• Branded
• Generics
• Global Adalimumab Market, By Therapeutic Area:
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Psoriasis
• Crohn’s Disease
• Others
• Global Adalimumab Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
• Global Adalimumab Market, By End User:
• Hospitals & Clinics
• Home Healthcare
• Others
• Global Adalimumab Market, By Region:
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Europe
• France
• Germany
• United Kingdom
• Italy
• Spain
• North America
• United States
• Mexico
• Canada
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global adalimumab market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

• Profit margin analysis in case of direct and indirect sales channel.

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

4.1. Adalimumab Demand, By Therapeutic Area
4.2. Adalimumab Demand, By Region
4.3. Adalimumab Demand, By Gender
4.4. Adalimumab Demand, By Patient Population
4.5. Commonly Observed Side-Effects
4.6. Brand Awareness

5. PHARMACODYNAMIC OVERVIEW OF ADALIMUMAB

5.1. Mechanism of Action
5.2. Absorption
5.3. Volume of Distribution
5.4. Route of Elimination
5.5. Half Life
5.6. Clearance
5.7. Toxicity

6. CLINICAL TRIALS

6.1. Ongoing Clinical Trials
6.2. Completed Clinical Trials
6.3. Terminated Clinical Trials
6.4. Clinical Trial Analysis

7. PATENT ANALYSIS

7.1. Patent Granted
7.2. Patent Applications Filed

8. GLOBAL ADALIMUMAB MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Type (Biologics v/s Biosimilars)
  8.2.2. By Product Type (Branded v/s Generics)
  8.2.3. By Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn’s Disease, Others)
  8.2.4. Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
  8.2.5. By End User (Hospitals & Clinics, Home Healthcare, Others)
  8.2.6. By Company (2022)
  8.2.7. By Region
8.3. Product Market Map

9. NORTH AMERICA ADALIMUMAB MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value & Volume
9.2. Market Share & Forecast
  9.2.1. By Type
  9.2.2. By Product Type
  9.2.3. By Therapeutic Area
  9.2.4. By Distribution Channel
  9.2.5. By End User
  9.2.6. By Country
9.3. North America: Country Analysis
  9.3.1. United States Adalimumab Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Type
      9.3.1.2.2. By Product Type
      9.3.1.2.3. By Therapeutic Area
      9.3.1.2.4. By Distribution Channel
      9.3.1.2.5. By End User
  9.3.2. Mexico Adalimumab Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Type
      9.3.2.2.2. By Product Type
      9.3.2.2.3. By Therapeutic Area
      9.3.2.2.4. By Distribution Channel
      9.3.2.2.5. By End User
  9.3.3. Canada Adalimumab Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Type
      9.3.3.2.2. By Product Type
      9.3.3.2.3. By Therapeutic Area
      9.3.3.2.4. By Distribution Channel
      9.3.3.2.5. By End User

10. EUROPE ADALIMUMAB MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value & Volume
10.2. Market Share & Forecast
  10.2.1. By Type
  10.2.2. By Product Type
  10.2.3. By Therapeutic Area
  10.2.4. By Distribution Channel
  10.2.5. By End User
  10.2.6. By Country
10.3. Europe: Country Analysis
  10.3.1. France Adalimumab Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Type
      10.3.1.2.2. By Product Type
      10.3.1.2.3. By Therapeutic Area
      10.3.1.2.4. By Distribution Channel
      10.3.1.2.5. By End User
  10.3.2. Germany Adalimumab Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Type
      10.3.2.2.2. By Product Type
      10.3.2.2.3. By Therapeutic Area
      10.3.2.2.4. By Distribution Channel
      10.3.2.2.5. By End User
  10.3.3. United Kingdom Adalimumab Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Type
      10.3.3.2.2. By Product Type
      10.3.3.2.3. By Therapeutic Area
      10.3.3.2.4. By Distribution Channel
      10.3.3.2.5. By End User
  10.3.4. Italy Adalimumab Market Outlook
    10.3.4.1. Market Size & Forecast
      10.3.4.1.1. By Value
    10.3.4.2. Market Share & Forecast
      10.3.4.2.1. By Type
      10.3.4.2.2. By Product Type
      10.3.4.2.3. By Therapeutic Area
      10.3.4.2.4. By Distribution Channel
      10.3.4.2.5. By End User
  10.3.5. Spain Adalimumab Market Outlook
    10.3.5.1. Market Size & Forecast
      10.3.5.1.1. By Value
    10.3.5.2. Market Share & Forecast
      10.3.5.2.1. By Type
      10.3.5.2.2. By Product Type
      10.3.5.2.3. By Therapeutic Area
      10.3.5.2.4. By Distribution Channel
      10.3.5.2.5. By End User

11. ASIA-PACIFIC ADALIMUMAB MARKET OUTLOOK

11.1. Market Size & Forecast
  11.1.1. By Value & Volume
11.2. Market Share & Forecast
  11.2.1. By Type
  11.2.2. By Product Type
  11.2.3. By Therapeutic Area
  11.2.4. By Distribution Channel
  11.2.5. By End User
  11.2.6. By Country
11.3. Asia-Pacific: Country Analysis
  11.3.1. China Adalimumab Market Outlook
    11.3.1.1. Market Size & Forecast
      11.3.1.1.1. By Value
    11.3.1.2. Market Share & Forecast
      11.3.1.2.1. By Type
      11.3.1.2.2. By Product Type
      11.3.1.2.3. By Therapeutic Area
      11.3.1.2.4. By Distribution Channel
      11.3.1.2.5. By End User
  11.3.2. India Adalimumab Market Outlook
    11.3.2.1. Market Size & Forecast
      11.3.2.1.1. By Value
    11.3.2.2. Market Share & Forecast
      11.3.2.2.1. By Type
      11.3.2.2.2. By Product Type
      11.3.2.2.3. By Therapeutic Area
      11.3.2.2.4. By Distribution Channel
      11.3.2.2.5. By End User
  11.3.3. South Korea Adalimumab Market Outlook
    11.3.3.1. Market Size & Forecast
      11.3.3.1.1. By Value
    11.3.3.2. Market Share & Forecast
      11.3.3.2.1. By Transgenic Crop
      11.3.3.2.2. By Technique
      11.3.3.2.3. By Application
      11.3.3.2.4. By End User
  11.3.4. Japan Adalimumab Market Outlook
    11.3.4.1. Market Size & Forecast
      11.3.4.1.1. By Value
    11.3.4.2. Market Share & Forecast
      11.3.4.2.1. By Type
      11.3.4.2.2. By Product Type
      11.3.4.2.3. By Therapeutic Area
      11.3.4.2.4. By Distribution Channel
      11.3.4.2.5. By End User
  11.3.5. Australia Adalimumab Market Outlook
    11.3.5.1. Market Size & Forecast
      11.3.5.1.1. By Value
    11.3.5.2. Market Share & Forecast
      11.3.5.2.1. By Type
      11.3.5.2.2. By Product Type
      11.3.5.2.3. By Therapeutic Area
      11.3.5.2.4. By Distribution Channel
      11.3.5.2.5. By End User

12. SOUTH AMERICA ADALIMUMAB MARKET OUTLOOK

12.1. Market Size & Forecast
  12.1.1. By Value & Volume
12.2. Market Share & Forecast
  12.2.1. By Type
  12.2.2. By Product Type
  12.2.3. By Therapeutic Area
  12.2.4. By Distribution Channel
  12.2.5. By End User
  12.2.6. By Country
12.3. South America: Country Analysis
  12.3.1. Brazil Adalimumab Market Outlook
    12.3.1.1. Market Size & Forecast
      12.3.1.1.1. By Value
    12.3.1.2. Market Share & Forecast
      12.3.1.2.1. By Type
      12.3.1.2.2. By Product Type
      12.3.1.2.3. By Therapeutic Area
      12.3.1.2.4. By Distribution Channel
      12.3.1.2.5. By End User
  12.3.2. Argentina Adalimumab Market Outlook
    12.3.2.1. Market Size & Forecast
      12.3.2.1.1. By Value
    12.3.2.2. Market Share & Forecast
      12.3.2.2.1. By Type
      12.3.2.2.2. By Product Type
      12.3.2.2.3. By Therapeutic Area
      12.3.2.2.4. By Distribution Channel
      12.3.2.2.5. By End User
  12.3.3. Colombia Adalimumab Market Outlook
    12.3.3.1. Market Size & Forecast
      12.3.3.1.1. By Value
    12.3.3.2. Market Share & Forecast
      12.3.3.2.1. By Type
      12.3.3.2.2. By Product Type
      12.3.3.2.3. By Therapeutic Area
      12.3.3.2.4. By Distribution Channel
      12.3.3.2.5. By End User

13. MIDDLE EAST AND AFRICA ADALIMUMAB MARKET OUTLOOK

13.1. Market Size & Forecast
  13.1.1. By Value & Volume
13.2. Market Share & Forecast
  13.2.1. By Type
  13.2.2. By Product Type
  13.2.3. By Therapeutic Area
  13.2.4. By Distribution Channel
  13.2.5. By End User
  13.2.6. By Country
13.3. MEA: Country Analysis
  13.3.1. South Africa Adalimumab Market Outlook
    13.3.1.1. Market Size & Forecast
      13.3.1.1.1. By Value
    13.3.1.2. Market Share & Forecast
      13.3.1.2.1. By Type
      13.3.1.2.2. By Product Type
      13.3.1.2.3. By Therapeutic Area
      13.3.1.2.4. By Distribution Channel
      13.3.1.2.5. By End User
  13.3.2. Saudi Arabia Adalimumab Market Outlook
    13.3.2.1. Market Size & Forecast
      13.3.2.1.1. By Value
    13.3.2.2. Market Share & Forecast
      13.3.2.2.1. By Type
      13.3.2.2.2. By Product Type
      13.3.2.2.3. By Therapeutic Area
      13.3.2.2.4. By Distribution Channel
      13.3.2.2.5. By End User
  13.3.3. UAE Adalimumab Market Outlook
    13.3.3.1. Market Size & Forecast
      13.3.3.1.1. By Value
    13.3.3.2. Market Share & Forecast
      13.3.3.2.1. By Type
      13.3.3.2.2. By Product Type
      13.3.3.2.3. By Therapeutic Area
      13.3.3.2.4. By Distribution Channel
      13.3.3.2.5. By End User

14. MARKET DYNAMICS

14.1. Drivers
14.2. Challenges

15. MARKET TRENDS & DEVELOPMENTS

16. COMPETITIVE LANDSCAPE

16.1. Abbvie Inc.
16.2. Pfizer, Inc.
16.3. Amgen Inc.
16.4. Novartis AG
16.5. Torrent Pharmaceuticals Ltd.
16.6. Cadila Healthcare Limited
16.7. Boehringer Ingelheim International GmbH
16.8. Mylan N.V.
16.9. Hetero Biopharma Ltd
16.10. Samsung Bioepis Co Ltd.

17. STRATEGIC RECOMMENDATIONS

18. ABOUT US & DISCLAIMER